title: [Topical immunomodulators: a therapeutic option for oral cicatricial pemphigoid].
abstract: Oral cicatricial pemphigoid is a chronic autoimmune blistering disease which affects predominantly the gingiva and the buccal mucosa. The pathogenesis of this disease is still incompletely understood; however, there is compelling evidence that cicatricial pemphigoid might be mediated by T lymphocytes. Therefore, we performed immunomodulatory therapy with topical tacrolimus in patients with long-standing, therapy-resistant oral cicatricial pemphigoid. Following 3 months of treatment, complete healing and ongoing remission could be achieved.
authors.affiliation: Hautklinik, Universitätsklinikum Düsseldorf, Düsseldorf.
authors.forename: T
authors.initials: T
authors.lastname: Assmann
authors.forename: T
authors.initials: T
authors.lastname: Burchardt
authors.forename: J
authors.initials: J
authors.lastname: Becker
authors.forename: T
authors.initials: T
authors.lastname: Ruzicka
authors.forename: M
authors.initials: M
authors.lastname: Megahed
mesh_terms: D000368:Aged; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005148:Facial Dermatoses / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D009059:Mouth Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D009824:Ointments; D010391:Pemphigoid, Bullous / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016559:Tacrolimus / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus